ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses12.28 M10.78 M15.02 M20.67 M21.01 M67.48 MResearch & development24.75 M20.81 M29.15 M24.79 M28.99 M103.74 MOperating income37.03 M31.59 M44.17 M43.76 M40.72 M160.24 MNon-Operating Income, Total908 K960 K1 M932 K1.22 M4.11 MInterest expense, net of interest capitalized1.15 M1.15 M192 K212 K319 K1.87 MNon-Operating Income, excl. Interest Expenses-317 K-178 K768 K610 K863 K2.06 MUnusual income/expense77 K-8 00040 K110 K37 K179 KPretax income37.87 M32.48 M46.99 M-18.66 M-10.18 M50.62 MEquity in earnings——————Taxes0185 K000185 KNon-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations23.97 M64.55 M52.1 M25.93 M98.52 M241.11 MDiscontinued operations——————Net income23.97 M64.55 M52.1 M25.93 M98.52 M241.11 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders23.97 M64.55 M52.1 M-46.25 M98.52 M168.92 MBasic earnings per share (Basic EPS)-0.54-1.49-0.96-0.34-1.38-4.17Diluted earnings per share (Diluted EPS)-0.6-1.49-0.96-0.62-1.35-4.42Average basic shares outstanding31.35 M35.71 M54.17 M60.19 M64.56 M214.64 MDiluted shares outstanding31.35 M35.71 M54.17 M68.18 M64.56 M222.63 MEBITDA———-43.32 M-38.75 M—EBIT———-43.57 M-39.47 M—Cost of revenue———128 K300 K—Other cost of goods sold——————Depreciation & amortization (cash flow)-194 K-200 K40 K255 K720 K815 K
Verastem Inc
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.